全文获取类型
收费全文 | 64394篇 |
免费 | 6274篇 |
国内免费 | 4761篇 |
专业分类
耳鼻咽喉 | 451篇 |
儿科学 | 866篇 |
妇产科学 | 599篇 |
基础医学 | 7021篇 |
口腔科学 | 1080篇 |
临床医学 | 8881篇 |
内科学 | 9152篇 |
皮肤病学 | 594篇 |
神经病学 | 2934篇 |
特种医学 | 2218篇 |
外国民族医学 | 29篇 |
外科学 | 6170篇 |
综合类 | 12477篇 |
现状与发展 | 19篇 |
一般理论 | 3篇 |
预防医学 | 4748篇 |
眼科学 | 1613篇 |
药学 | 7223篇 |
65篇 | |
中国医学 | 4231篇 |
肿瘤学 | 5055篇 |
出版年
2024年 | 227篇 |
2023年 | 1017篇 |
2022年 | 2537篇 |
2021年 | 3143篇 |
2020年 | 2452篇 |
2019年 | 1990篇 |
2018年 | 2062篇 |
2017年 | 2058篇 |
2016年 | 1920篇 |
2015年 | 2942篇 |
2014年 | 3695篇 |
2013年 | 3403篇 |
2012年 | 4917篇 |
2011年 | 5471篇 |
2010年 | 3694篇 |
2009年 | 3009篇 |
2008年 | 3669篇 |
2007年 | 3752篇 |
2006年 | 3499篇 |
2005年 | 3187篇 |
2004年 | 2328篇 |
2003年 | 2228篇 |
2002年 | 1910篇 |
2001年 | 1647篇 |
2000年 | 1462篇 |
1999年 | 1364篇 |
1998年 | 777篇 |
1997年 | 854篇 |
1996年 | 601篇 |
1995年 | 529篇 |
1994年 | 460篇 |
1993年 | 322篇 |
1992年 | 350篇 |
1991年 | 355篇 |
1990年 | 295篇 |
1989年 | 256篇 |
1988年 | 200篇 |
1987年 | 193篇 |
1986年 | 163篇 |
1985年 | 101篇 |
1984年 | 62篇 |
1983年 | 41篇 |
1982年 | 23篇 |
1981年 | 27篇 |
1980年 | 28篇 |
1979年 | 49篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
2.
3.
患者男,64岁,因头颅增大、面部变长,颧骨隆起、下颌增大、双手掌肥厚、双手指粗短30余年,乳房肿物1年余就诊。患者30余年前无明显诱因出现渐进性手足增大,双手掌肥厚,嘴唇变厚,下颌增大,眉弓及颧骨突出,皮肤增厚,无乳腺增大、泌乳,未诊治…… 相似文献
4.
5.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
6.
7.
目前新型冠状病毒肺炎(COVID-19)疫情在全球蔓延,形势严峻,并对全球公共卫生事业构成巨大挑战,快速准确的诊断COVID-19对疫情的防控有重要意义。本文报道1例COVID-19患者的调查和确诊过程,以对COVID-19确诊和疫情防控提供有价值的参考。患者为赴渝务工于2020年1月23日返乡人员,在渝期间,其同工地的一同事确诊为COVID-19,之后该工地接连有另外8位同事被确诊。患者返乡后2月2日被当地疫情防控单位采取医学隔离。患者于隔离后不久出现咳嗽,阵发性,干咳为主,偶可咳出黄色痰液等COVID-19相关临床症状,遂被当地新型冠状病毒肺炎定点医疗单位收治,后经市级新型冠状病毒肺炎诊治专家组远程视频会诊转入四川大学华西医院资阳医院。患者先后经历9次核酸检测,在前8次核酸检测均为阴性的情况下,于第9次核酸检测结果为阳性,2月21日最终确诊为新型冠状病毒肺炎。 相似文献
8.
9.
10.
向楠教授系湖北中医药大学二级教授、主任医师、博士生导师,湖北中医名师、首届湖北省中青年知名中医、武汉中青年中医名医,培养学术继承人及硕士、博士等50余名,从事中医临床、教学、科研工作30余载,擅长应用中医药防治内分泌及代谢性疾病。余有幸跟师学习,受益颇深,现将其治疗亚急性甲状腺炎的经验总结于下,与同道共享。 相似文献